Contact us
Close

Getting in touch

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean condimentum justo massa, ut dapibus nisl vestibulum ac. Vestibulum dapibus dui ac tortor gravida pellentesque. Nam ut velit non sapien vulputate volutpat in pretium dui. Mauris malesuada urna et metus dignissim, cursus tincidunt.

Clinical trials

A ‘clinical trial’ is a research study in which people agree to test a potential new treatment to prevent or improve a disease or medical condition. A clinical trial also looks at how participants react to the potential new treatment and if any unwanted effects occur. This helps to determine if the new investigational treatment works, is safe, and is better than those that are already available. Many clinical trials also compare existing treatments or test new ways to use or combine existing treatments.

A.

Clinical Trial of Debio 1562 in non-Hodgkin lymphoma

Debiopharm International is conducting an open-label Definition An open-label trial means that no placebo is administered and that patients know what treatment they are given. non-randomized two-part Phase II trial in male and female patients with diffuse large B cell lymphoma and other types of NHL.

The first part of this trial aims at evaluating the safety of Debio 1562 Definition Debio 1562 (IMGN529), an antibody-drug conjugate (anti-CD37 ADC), is a potential new treatment for patients with B-cell malignancies, such as non-Hodgkin lymphoma (NHL). Debio 1562 demonstrated evidence of anti-cancer activity in NHL in a Phase 1 monotherapy trial and successfully completed a safety lead-in study in combination with Rituxan®. The product is now ready to enter into expansion in NHL and particularly in relapsed/refractory diffuse large-cell B-cell lymphoma (R/R DLBCL) for which it benefits from Orphan Drug status. More info: http://bit.ly/2hDaqoi (Debio 1562 Definition Debio 1562 (IMGN529), an antibody-drug conjugate (anti-CD37 ADC), is a potential new treatment for patients with B-cell malignancies, such as non-Hodgkin lymphoma (NHL). Debio 1562 demonstrated evidence of anti-cancer activity in NHL in a Phase 1 monotherapy trial and successfully completed a safety lead-in study in combination with Rituxan®. The product is now ready to enter into expansion in NHL and particularly in relapsed/refractory diffuse large-cell B-cell lymphoma (R/R DLBCL) for which it benefits from Orphan Drug status. More info: http://bit.ly/2hDaqoi is an investigational medicine product) combined with rituximab Definition a drug already on the market for several of these diseases. in patients with diffuse large B cell lymphoma, follicular lymphoma, mantle cell lymphoma and marginal zone lymphoma/mucosa-associated lymphoid tissue. Debio 1562 Definition Debio 1562 (IMGN529), an antibody-drug conjugate (anti-CD37 ADC), is a potential new treatment for patients with B-cell malignancies, such as non-Hodgkin lymphoma (NHL). Debio 1562 demonstrated evidence of anti-cancer activity in NHL in a Phase 1 monotherapy trial and successfully completed a safety lead-in study in combination with Rituxan®. The product is now ready to enter into expansion in NHL and particularly in relapsed/refractory diffuse large-cell B-cell lymphoma (R/R DLBCL) for which it benefits from Orphan Drug status. More info: http://bit.ly/2hDaqoi has been well tolerated in a previous clinical trial.

The purpose of the second part of this trial, which is in the planning stage, is to evaluate the efficacy of Debio 1562 Definition Debio 1562 (IMGN529), an antibody-drug conjugate (anti-CD37 ADC), is a potential new treatment for patients with B-cell malignancies, such as non-Hodgkin lymphoma (NHL). Debio 1562 demonstrated evidence of anti-cancer activity in NHL in a Phase 1 monotherapy trial and successfully completed a safety lead-in study in combination with Rituxan®. The product is now ready to enter into expansion in NHL and particularly in relapsed/refractory diffuse large-cell B-cell lymphoma (R/R DLBCL) for which it benefits from Orphan Drug status. More info: http://bit.ly/2hDaqoi combined with rituximab Definition a drug already on the market for several of these diseases. in patients with diffuse large B cell lymphoma and other forms of NHL. Patients will be treated with Debio 1562 Definition Debio 1562 (IMGN529), an antibody-drug conjugate (anti-CD37 ADC), is a potential new treatment for patients with B-cell malignancies, such as non-Hodgkin lymphoma (NHL). Debio 1562 demonstrated evidence of anti-cancer activity in NHL in a Phase 1 monotherapy trial and successfully completed a safety lead-in study in combination with Rituxan®. The product is now ready to enter into expansion in NHL and particularly in relapsed/refractory diffuse large-cell B-cell lymphoma (R/R DLBCL) for which it benefits from Orphan Drug status. More info: http://bit.ly/2hDaqoi and rituximab Definition a drug already on the market for several of these diseases. by intravenous injection on the same day once every three weeks.

  • _Phases

    • P
    • M
B.

Talk with your medical doctor

If you are interested in participating in an upcoming clinical trial, ask your doctor if a clinical trial might be right for you. Your doctor knows both you and your health history, which is invaluable in making this decision. Your doctor can help you gather the information needed to locate a trial and help you identify what questions might be important to ask before deciding to participate. When you join a clinical trial, you will still receive care from your primary doctor for your overall health. Most trials are only for a limited time and only pertain to the condition being studied.

C.

Find the trials on the map

Back to the pathologies